Precision for Medicine
Jen VanceSenior Director
Jen Vance is a seasoned hematology/oncology expert at Precision, bringing over 20 years of experience in the CRO industry. She has a proven track record in portfolio management, clinical development planning, therapeutic strategy, and providing in-depth therapeutic expertise. Jen has extensive experience in hematology-oncology drug development, spanning Phase 1 to Phase 4 clinical trials. She specializes in hematologic malignancies and has worked across a broad range of therapeutic approaches, including traditional chemotherapies, targeted therapies, cell therapies, chemotherapies, checkpoint inhibitors, bispecific antibodies and anti-body drug conjugates. Jen has extensive expertise in both myeloid and lymphoid hematologic malignancies, with a focus on a wide range of conditions. Her experience includes working with myelodysplastic syndromes, myelofibrosis, acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and chronic myelomonocytic leukemia (CMML). In the lymphoid malignancy space, Jen has significant experience with acute lymphoblastic leukemia (ALL), as well as a broad range of non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), and Waldenström macroglobulinemia (WM). Jen blends deep therapeutic insight with strategic operational expertise to help clients accelerate the path from molecule development to market. Her ability to navigate both the scientific and operational aspects of drug development ensures efficient, targeted progress toward regulatory approval and commercialization.
Insights from Jen Vance
Research & Development | White Paper
Breaking Through in Hematologic Malignancies